All In Biotech

NDA 220201 · Avyxa Holdings

Favlyxa

Fluorouracil · Intravenous · Nucleoside Metabolic Inhibitor

Last checked: Nov 19, 2026Latest source record: Feb 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Feb 20, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4,755

1,167 Phase 3, 630 recruiting

FAERS reports

77,573

73,662 serious, 10,971 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS ADVERSE REACTIONS OR DEATH IN PATIENTS WITH COMPLETE DPD DEFICIENCY Increased risk of serious adverse reactions or death in patients with complete DPD deficiency. Test patients for genetic variants of DPYD prior to initiating FAVLYXA unless immediate treatment is necessary. Avoid use of FAVLYXA in patients with certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficiency [see Warnings and Precautions (5.1) ]. WARNING: SERIOUS ADVERSE REACTIONS OR DEATH IN PATIENTS WITH COMPLETE DPD DEFICIENCY Increased risk of serious adverse reactions or death in patients with complete DPD deficiency. Test patients for genetic variants of DPYD prior to initiating FAVLYXA unless immediate treatment is necessary. Avoid use of FAVLYXA in patients with certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficiency. ( 5.1...

What it is approved for

From the label in effect Oct 23, 2026.

FAVLYXA is indicated for the treatment of patients with: FAVLYXA is a nucleoside metabolic inhibitor indicated for the treatment of patients with: Adenocarcinoma of the Colon and Rectum ( 1.1 ) Adenocarcinoma of the Breast ( 1.2 ) Gastric Adenocarcinoma ( 1.3 ) Pancreatic Adenocarcinoma ( 1.4 ) 1.1 Adenocarcinoma of the Colon and Rectum 1.2 Adenocarcinoma of the Breast 1.3 Gastric Adenocarcinoma 1.4 Pancreatic Adenocarcinoma

Mechanism: Fluorouracil is a nucleoside metabolic inhibitor that interferes with the synthesis of deoxyribonucleic acid (DNA) and to a lesser extent inhibits the formation of ribonucleic acid (RNA); these affect rapidly growing cells and may lead to cell death. Fluorouracil is converted to three main active metabolites: 5-fluoro-2′-deoxyuridine-5′-monophosphate (FdUMP), 5-fluorouridine-5′triphosphate (FUTP) and 5-fluoro-2′-deoxyuridine-5′-triphosphate (FdUTP). These metabolites have several effects including the inhibition of thymidylate synthase by FdUMP, incorporation of FUTP into RNA and...

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 20, 2026 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabel
2 products under this application
  • FAVLYXA · FLUOROURACIL 2.5GM/100ML (25MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • FAVLYXA · FLUOROURACIL 250MG/10ML (25MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluorouracil" as an intervention, any sponsor and status, largest first.

All 4,755 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea7,076
  • neutropenia5,294
  • nausea5,063
  • vomiting4,037
  • off label use3,617
  • neuropathy peripheral3,541
  • fatigue3,319
  • disease progression3,293
  • pyrexia3,085
  • thrombocytopenia3,036
  • febrile neutropenia2,915
  • anaemia2,610

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,695
20051,687
20061,392
20071,586
20081,848
20091,815
20101,692
20112,338
20122,862
20132,240
20141,876
20152,381
20162,750
20173,197
20184,843
20195,095
20204,261
20214,265
20225,711
20236,300
20245,981
20256,681
20265,077

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8,452 on PubMed

Sponsor: Avyxa Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.